期刊文献+

淋巴管畸形的硬化治疗 被引量:11

Sclerotherapy of Lymphatic Malformations in the Head and Neck
暂未订购
导出
摘要 淋巴管畸形是一种常见的脉管畸形。硬化治疗是一种常用的治疗方法,临床将其作为一线治疗均获得较满意的疗效且无明显并发症。目前应用的硬化剂种类繁多,但没有一种能适应于所有病变。由于病变类型不同及使用的硬化剂不同,回顾性研究的结果也不一致。较多的临床研究表明,大囊型淋巴管畸形硬化治疗的疗效优于微囊型,对于大囊型病变或以大囊成分为主的混合型病变建议应用OK432或平阳霉素治疗,而微囊型病变则可选用强力霉素或平阳霉素。弥漫性微囊型淋巴管畸形的治疗仍然是一项具有挑战性的工作,常需硬化治疗与手术或激光治疗相结合。有关淋巴管畸形尤其是微囊型病变的硬化治疗药物及治疗方法尚需进一步研究。 Lymphatic malformations are common vascular anomalies in the head and neck.Percutaneous sclerotherapy of lymphatic malformations as the first-line treatment has been widely used and had satisfactory outcomes without severe complications in most of the cases.Many sclerosants have clinically been applied,but none of them can cure all malformations.Results vary from series to series,which probably reflect the complexity of lymphatic malformations and the varieties of sclerosing agents are in use.It is recommended that macrocystic or mixed lesions with larger cyst cavity can be treated by intralesional injection of OK-432 or pinyangmycin,and microcystic type is sclerosed applying doxycycline or pinyangmycin.The management of extensive lymphatic malformations in the head and neck regions is still challenging, usually in combination with surgical excision and laser.The better sclerosants and sclerosant techniques should be developed especially in management of microcystic lymphatic malformations.
出处 《口腔颌面外科杂志》 CAS 2011年第1期1-6,共6页 Journal of Oral and Maxillofacial Surgery
关键词 淋巴管畸形 硬化治疗 硬化剂 lymphatic malformations sclerotherapy sclerosants
  • 相关文献

参考文献38

  • 1Waner M,Suen JY.Hemangiomas and vascular malformations of the head and neck[M].New York:Wiley-Liss,1999:69-74.
  • 2Hartl DM,Roger G,Denoyelle F,et al.Extensive lymphangioma presenting with upper airway obstruction[J].Arch Otolaryngol Head Neck Surg,2000,126 (11):1378-1382.
  • 3Lei ZM,Huang XX,Sun ZJ,et al.Surgery of lymphatic malformations in oral and cervicofacial regions in children[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2007,104(3):338-344.
  • 4Perkins JA,Manning SC,Tempero RM,et al.Lymphatic malformations:review of current treatment[J].Otolaryngol Head Neck Surg,2010,142(6):795-803.
  • 5Tammela T,Enholm B,Alitalo K,et al.The biology of vascular endothelial growth factors[J].Cardiovasc Res,2005,65(3):550-563.
  • 6Huany HY,Ho CC,Huang PH,et al.Co-expression of VEGF-C and its receptors,VEGFR-2 and VEGFR-3,in endothelial cells of lymphangioma.Implication in autocrine or paracrine regulation of lymphangioma[J].Lab Invest,2001,81(12):1729-1734.
  • 7白轶,孙志军,赵怡芳.淋巴管畸形病变发生机制的研究进展[J].国际口腔医学杂志,2006,33(5):384-386. 被引量:3
  • 8Acevedo JL,Shah RK,Brietzke SE.Nonsurgical therapies for iymphangiomas:a systematic review[J].Otolaryngul Head Neck Surg,2008,138(4):418-424.
  • 9Nehra D,Jacobson L,Barnes P,et al.Doxycycline sclerotherapy as primary treatment of head and neck lymphatic malformations in children[j].J Pediatr Surg,2008,43(3):451-460.
  • 10Shiels WE 2nd,Kang DR,Murakami JW,et al.Pereutaneous treatment of lymphatic malformations[J].Otolaryngol Head Neck Surg,2009,141(2):219-224.

二级参考文献51

  • 1寿柏泉,杨震,孟昭业,南福清,郑葆春.平阳霉素治疗颌面部草莓状和混合性血管瘤225例的临床总结[J].华西口腔医学杂志,1995,13(3):198-200. 被引量:63
  • 2张文峰,钟林生.平阳霉素瘤内注射治疗颌面部血管瘤[J].口腔医学纵横,1995,11(2):100-101. 被引量:30
  • 3蒋嘉萍,谷兴琳.平阳霉素治疗小儿淋巴瘤100例分析[J].中华外科杂志,1989,27(12):741-742. 被引量:15
  • 4Joukov V, Sorsa T, Kumar V, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. Embo J, 1997, 16(13)∶3 898-3 911
  • 5Claesson-Welsh L. Vascular growth factors and angiogenesis. Berlin: Springer-Verlag,1999,89
  • 6Shibuya M. Role of VEGF-Flt receptor system in normal and tumor angiogenesis. Adv Cancer Res, 1995, 67∶281-316
  • 7Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol, 1995, 129(4)∶895-898
  • 8Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA, 1998, 95(2)∶548-553
  • 9Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem, 1992, 267(36)∶2 6031-2 6037
  • 10Kukk E, Lymboussaki A, Taira S, et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development, 1996, 122(12)∶3 829-3 837

共引文献31

同被引文献120

引证文献11

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部